



NDA 21472/S-015

**SUPPLEMENT APPROVAL**

Bionpharma, Inc.  
Attention: Usha Sankaran  
Associate Vice President, Regulatory Affairs  
600 Alexander Road, Suite 2-4B  
Princeton, NJ 08540

Dear Ms. Sankaran:

Please refer to your supplemental new drug application (sNDA) dated and received May 28, 2021, and your amendment, submitted pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act (FDCA) for ibuprofen capsules, 200 mg.

This “Changes Being Effectuated” supplemental new drug application provides for an update under the “If pregnant or breast-feeding” warning on the Drug Facts labeling in response to the Agency’s CBE Supplement Request letter dated April 28, 2021.

**APPROVAL & LABELING**

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

**LABELING**

Submit final printed labeling (FPL), as soon as they are available, but no more than 30 days after they are printed. The FPL must be identical to the labeling listed in the table below and must be in the “Drug Facts” format (21 CFR 201.66), where applicable.

<b>Submitted Labeling</b>	<b>Submission Date</b>
20-count outer carton	September 16, 2021
200-count immediate container	May 28, 2021
200-count outer carton	May 28, 2021

The FPL should be submitted electronically according to the guidance for industry *Providing Regulatory Submissions in Electronic Format — Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications*.<sup>1</sup> For administrative purposes, designate this submission “**Final Printed Labeling for approved NDA 21472/S-015.**” Approval of this submission by FDA is not required before the labeling is used.

### **DRUG REGISTRATION AND LISTING**

All drug establishment registration and drug listing information is to be submitted to FDA electronically, via the FDA automated system for processing structured product labeling (SPL) files (eLIST). At the time that you submit your final printed labeling (FPL), the content of labeling (Drug Facts) should be submitted in SPL format as described at FDA.gov.<sup>2</sup> Information on submitting SPL files using eLIST may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*. In addition, representative container or carton labeling, whichever includes Drug Facts, (where differences exist only in the quantity of contents statement) should be submitted as a JPG file.

### **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Helen Lee, Safety Regulatory Project Manager, at 301-796-6848.

Sincerely,

*{See appended electronic signature page}*

Valerie Pratt, MD  
Deputy Director for Safety  
Division of Nonprescription Drugs I  
Office of Nonprescription Drugs  
Center for Drug Evaluation and Research

### ENCLOSURE(S):

- Carton and Container Labeling

---

<sup>1</sup> We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

<sup>2</sup> <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

-----  
**This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.**  
-----

/s/  
-----

VALERIE S PRATT  
10/21/2021 01:19:36 PM